Creative Medical Technology Holdings (CELZ) Total Debt (2010 - 2023)
Creative Medical Technology Holdings (CELZ) posted quarterly Total Debt of $14194.0 for Q1 2023, little changed year-over-year from $14194.0 in Q1 2022, and little changed quarter-over-quarter from $14194.0 in Q4 2022.
Creative Medical Technology Holdings (CELZ) Total Debt (2010 - 2023) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Total Debt for 14 consecutive years, with $14194.0 the latest figure, recorded in Q1 2023.
- In Q1 2023, Total Debt changed 0.0% year-over-year to $14194.0; the TTM figure through Mar 2023 stood at $14194.0 (changed 0.0% YoY), while the FY2022 annual figure was $14194.0, changed 0.0% from the prior year.
- Total Debt held at $14194.0 in Q1 2023 per CELZ's latest filing, from $14194.0 in the prior quarter.
- Across five years, Total Debt topped out at $237300.0 in Q2 2021 and bottomed at $10800.0 in Q1 2019.
- Historically, Total Debt has averaged $26997.9 across 5 years, with a median of $14194.0 in 2021.
- Annual changes were most pronounced in 2021 — Total Debt surged 2097.22% — and 2022, when it sank 94.02%.
- Creative Medical Technology Holdings' Total Debt stood at $10800.0 in 2019, then changed by 0.0% to $10800.0 in 2020, then surged by 31.43% to $14194.0 in 2021, then changed by 0.0% to $14194.0 in 2022, then changed by 0.0% to $14194.0 in 2023.
- Business Quant data shows CELZ's Total Debt at $14194.0 in Q1 2023, $14194.0 in Q4 2022, and $14194.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.07 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 546.77 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.34 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 770.36 Mn |
| 10 | Creative Medical Technology Holdings | 1.83 Mn | 1.83 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 14,194.00 |
| Dec 31, 2022 | 14,194.00 |
| Sep 30, 2022 | 14,194.00 |
| Jun 30, 2022 | 14,194.00 |
| Mar 31, 2022 | 14,194.00 |
| Dec 31, 2021 | 14,194.00 |
| Sep 30, 2021 | 17,300.00 |
| Jun 30, 2021 | 237,300.00 |
| Mar 31, 2021 | 32,800.00 |
| Dec 31, 2020 | 10,800.00 |
| Sep 30, 2020 | 10,800.00 |
| Jun 30, 2020 | 10,800.00 |
| Mar 31, 2020 | 10,800.00 |
| Dec 31, 2019 | 10,800.00 |
| Sep 30, 2019 | 10,800.00 |
| Jun 30, 2019 | 10,800.00 |
| Mar 31, 2019 | 10,800.00 |
| Dec 31, 2018 | 10,800.00 |
| Sep 30, 2018 | 10,800.00 |
| Jun 30, 2018 | 10,800.00 |